Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis

Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin. Prognosis is poor, with limited treatment options available, and the median survival remains just 3–5 years. Despite the use of pirfenidone and nintedanib for the treatment of IPF, curative therapies rem...

Full description

Bibliographic Details
Main Authors: Argyrios Tzouvelekis, Rebecca Toonkel, Theodoros Karampitsakos, Kantha Medapalli, Ioanna Ninou, Vasilis Aidinis, Demosthenes Bouros, Marilyn K. Glassberg
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Medicine
Subjects:
idiopathic pulmonary fibrosis
mesenchymal stem cells
treatment
safety
efficacy
Online Access:http://journal.frontiersin.org/article/10.3389/fmed.2018.00142/full

Internet

http://journal.frontiersin.org/article/10.3389/fmed.2018.00142/full

Similar Items